Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Chongyuan Xu"'
Publikováno v:
HemaSphere, Vol 7, p e66414ba (2023)
Externí odkaz:
https://doaj.org/article/942c2e96d3fa449ab9fdd123702e1135
Publikováno v:
Land, Vol 11, Iss 9, p 1573 (2022)
Carbon metabolism research has attracted worldwide attention as an important way to cope with climate change, promote carbon emission reduction, increase carbon sequestration, and support low-carbon city construction. Ecological network analysis (ENA
Externí odkaz:
https://doaj.org/article/ef788e8378524cea97ad7bcefc4c3683
Autor:
Xun Kang, Wenbin Ma, Weiping Li, Songtao Qi, Chongyuan Xu, Xuejun Yang, Liming Wang, Chao Gao, Feng Chen, Ce Wang, Zhuang Kang, Chuanlu Jiang, Wenbin Li
Publikováno v:
Current Medicine. 1
Background Treatment options for malignant and aggressive glioma are limited. Vascular endothelial growth factor (VEGF) antibodies are angiogenesis inhibitors that prevent the growth of neoplasms by inhibiting the expansion of the vascular tissue tha
Autor:
Hirst, Giles, Budhwar, Pawan, Cooper, Brian K., West, Michael, Long, Chen, Chongyuan, Xu, Shipton, Helen
Publikováno v:
Journal of International Business Studies, 2008 Dec 01. 39(8), 1343-1358.
Externí odkaz:
https://www.jstor.org/stable/25483350
Autor:
Jianyong Li, Keshu Zhou, Weiqi Nian, Guohui Cui, Jishi Wang, Xiaoping Zhang, Hong Cen, Fei Li, Shuhua Yi, Ru Feng, Chongyuan Xu, Wenbin Qian, Lihong Liu, Caixia Li, Xielan Zhao, Zi Chen, Junxiao Qiao, Hongli Zhang, Mohammad Ahmad, Yifan Zhai
Publikováno v:
Journal of Clinical Oncology. 40:7543-7543
7543 Background: B-cell malignancies evade apoptosis by overexpressing BCL-2 proteins. Approved BCL-2i venetoclax requires a slow dose ramp-up to limit risk of tumor lysis syndrome (TLS) and has been associated with severe neutropenia. Investigationa
Autor:
Zhen Liu, Huilai Zhang, Yan Sun, Shanzhi Gu, Dan Liu, Liling Zhang, Jun Lv, Ping Lu, Jifang Gong, Jianming Guo, Chunguang Ma, Lin Shen, Wang Xiang, Peijian Peng, Qi Li, Jianji Pan, Hang Su, Yuqin Song, Xianli Yin, Chongyuan Xu, Bangwei Cao, Li Chen, Dingwei Ye, Weiqing Han, Ou Jiang, Lulin Ma, Yongsheng Jiang, Guojun Zhang, Haiying Dong, Feng Zhang, Junyuan Qi, Jianhua Chen, Li Wang, Yuxian Bai, Yi Ba, Weiwei Ouyang, Siyang Wang, Y Guo
Publikováno v:
European journal of cancer (Oxford, England : 1990). 148
Background GLS-010, a novel engineered fully human immunoglobin G4 monoclonal antibody, can specially block the PD-1/PD-L1/2 axis and reactivate the antitumor immunity. Aim This phase Ia/Ib study was carried out to evaluate the safety, recommended ph
Autor:
Lingli Zhang, Yi Ba, Xianli Yin, Wang Xiang, Ge Jin, Xiangying Liang, Ping Lu, Jifang Gong, Guodong Zhao, Qi Li, Jianji Pan, Peijian Peng, Zhaoyang Pan, Yuqin Song, Dingwei Ye, Christopher S. Chen, Yuxian Bai, Jing Li, Jun Lv, Hang Su, Haiying Dong, H. Zhang, Li Wang, Fan Yang, Yong Zheng, Haijin Meng, Li Chen, Chunguang Ma, Kehui Xu, Jianming Guo, Jianhua Chen, Yan Sun, Bangwei Cao, Weiqing Han, Lin Shen, Shanzhi Gu, Junyuan Qi, Yongsheng Jiang, Zhihao Lu, Y Guo, Ou Jiang, Chongyuan Xu, Guojun Zhang, Feng Zhang, Siyang Wang, Yining Yang, Weiwei Ouyang
Publikováno v:
Cancer Research. 80:3275-3275
Background: GLS-010 is a novel fully human anti-PD-1 mAb developed by the OMT transgenic rat platform. In Phase 1a study, GLS-010 exhibited good tolerance and 240mg (Q2W) was selected. Phase 1b study was conducted to evaluate the safety,anti-tumor ac